Top

Published in:

Open Access 01-12-2007 | Short communication

t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia

Authors: Delong Liu, Josif Shimonov, Suneeta Primanneni, Yongrong Lai, Tauseef Ahmed, Karen Seiter

Published in: Molecular Cancer | Issue 1/2007

Abstract

Burkitt's lymphoma (BL) is a heterogeneous group of highly aggressive mature B-cell malignancies. It is characterized by a high rate of turnover of malignant cells and deregulation of the c-myc gene. It is typically associated with a t(8;14) translocation. Dual translocation of t(8;14) (c-myc) and t(14;18) (bcl-2) was reported to be associated with extremely poor prognosis. This study reports a novel t(8;14;18) triple translocation in two patients with Burkitt's lymphoma.

Available only for authorised users

Hecht JL, Aster JC: Molecular Biology of Burkitt's Lymphoma. J Clin Oncol. 2000, 18: 3707-3721.PubMed

Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol. 1996, 14: 2480-2485.PubMed

Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood. 2004, 104: 3009-3020. 10.1182/blood-2004-02-0405CrossRefPubMed

Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M: Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1999, 17: 2461-2470.PubMed

Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJS, Gascoyne RD, Horsman DE: Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia. 2005, 19: 659-663.PubMed

Van Ooteghem RB, Smit EM, Beishuizen A, Lambrechts AC, Blij-Philippsen M, Smilde TJ, Hagemeijer : A new B-cell line showing a complex translocation (8;14;18) and BCL2 rearrangement. Cancer Genet Cytogenet. 1994, 74: 87-94. 10.1016/0165-4608(94)90003-5CrossRefPubMed

Dyer MJ, Lillington DM, Bastard C, Tilly H, Lens D, Heward JM, Stranks G, Morilla R, Monard S, Guglelmi P, Kluin-Nelemans JC, Hagemeijer A, Young BD, Catovsky D: Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia. 1996, 10: 1198-1208.PubMed

Zimonjic DB, Keck-Waggoner C, Popescu NC: Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's lymphoma. Leukemia. 2001, 15: 1582-1588. 10.1038/sj.leu.2402281CrossRefPubMed

Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, Gascoyne RD: Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation. J Clin Oncol. 1999, 17: 1558-1567.PubMed

10.

Thangavelu M, Olopade O, Beckman E, Vardiman JW, Larson RA, McKeithan TW, Le Beau MM, Rowley JD: Clinical, Morphologic, cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14) (q24;q32) or t(8;22) (q24;q11). Genes Chromosomes Cancer. 1990, 2: 147-158. 10.1002/gcc.2870020211CrossRefPubMed

11.

Karsan A, Gascoyne RD, Coupland RW, Shepherd JD, Phillips GL, Horsman DE: Combination of t(14;18) and Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma. 1991, 10: 433-44.CrossRef

12.

Brito-Babapule V, Crawford A, Khokhar T, Laffan M, Matutes E, Fairhead S, Catovsky D: Translocations t(14;18) and t(8;14) with rearranged bcl-2 and c-myc in a case presenting as B-ALL (L3). Leukemia. 1991, 5: 83-87.

13.

Zani VJ, Asou N, Jadayel D, Heward JM, Shipley J, Nacheva E, Takasuki K, Catovsky D, Dyer MJS: Molecular cloning of complex chromosomal translocation t(8;14;12) (q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. Blood. 1996, 87: 3124-3134.PubMed

14.

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma E-J, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink H, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Caspo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006, 354: 2431-2442. 10.1056/NEJMoa055759CrossRefPubMed

15.

Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH: Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma – outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. JCO. 1996, 14: 2465-2472.

16.

Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T: Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant. 2000, 26: 1351-1354. 10.1038/sj.bmt.1702730CrossRefPubMed

17.

Grigg A, Seymour J: Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma. 2002, 43: 889-892. 10.1080/10428190290017051CrossRefPubMed

18.

Liu D, Seiter K, Chiao JW, Shi Q, Qureshi A, Jeong W, Nelson J, Ahmed T: Mitoxantrone, AraC, and Pentostatin (MAP regimen): phase I study of a novel non-myeloablative conditioning regimen for hematological malignancies. Int J Cancer Research. 2006, 2: 131-142.CrossRef

Title: t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia
Authors: Delong Liu
Josif Shimonov
Suneeta Primanneni
Yongrong Lai
Tauseef Ahmed
Karen Seiter
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-6-35

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation

Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth

Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer

Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia

DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets

In silico gene expression analysis – an overview

Keynote webinar | Spotlight on antibody–drug conjugates in cancer